Emily Mwakichako
Family · Dallas, TXNPI 1740928605
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,409 and has fallen 98.8% since, to $17 in 2025.
Across 103 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$417
- AbbVie$272
- AstraZeneca$191
- Lundbeck LLC$114
- GSK$103
- Pfizer$87
- plus $644 from 18 others
What the payments were for
- Food & beverage$1,828100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $417 |
| AbbVie | 16 | $272 |
| AstraZeneca | 10 | $191 |
| Lundbeck LLC | 5 | $114 |
| GSK | 6 | $103 |
| Pfizer | 5 | $87 |
| Lilly USA, LLC | 5 | $86 |
| Amgen | 4 | $66 |
| Johnson & Johnson | 3 | $55 |
| Noven Therapeutics, LLC | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Bayer | 2 | $40 |
| Novartis | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Corcept Therapeutics | 1 | $24 |
| Merck | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Alvogen Inc | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$1,828 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 25 | $236 |
| Alendronate Sodium | 21 | $179 |
| Levothyroxine Sodium | 16 | $167 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $73 |
| Montelukast Sodium | 12 | $70 |
| Metformin Hcl | 13 | $58 |
Paid to pharmacies, not to this prescriber.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.